Measure ID: MIPS 420·Vascular Disease·2026 Performance Year

2026 MIPS Measure #420: Varicose Vein Treatment with Saphenous Ablation: Outcome Survey

Percentage of patients treated for varicose veins (CEAP C2-S) who are treated with saphenous ablation (with or without adjunctive tributary treatment) that report an improvement on a disease specific patient reported outcome survey instrument after treatment.

Patient Reported Outcome-Based Performance Measure – High PriorityVascular DiseasePatient-Reported Outcomes

Measure ID:MIPS 420 (Quality ID 420)

Collection:MIPS CQM

Topped Out:No

View CMS Spec ↗

Measure Specification

Eligible Population

All patients, regardless of age

ANDDiagnosis for varicose veins

ANDPatient procedure during the performance period

Exclusions

None

Numerator

Patients whose outcome survey score improved when assessed within 180 days following treatment.

Reporting Codes

Performance Met:

G9603Patient survey score improved from baseline following treatment

Performance Not Met:

G9605Patient survey score did not improve from baseline following treatment

M1464No documentation of at least two attempts to follow up with patient within 180 days of treatment

M1465Patient follow up more than 180 days after treatment

○ Exceptions:

M1463Documentation of at least two attempts to follow up with patient within 180 days of treatment

VBCA Insights

Why This Measure Matters

This measure asks whether patients actually feel better after vein ablation surgery for varicose veins, not just whether the veins look better on imaging. Patient quality of life—reduced pain, swelling, and skin changes—is what truly matters for a successful procedure. You'll track symptom improvement using a standardized survey patients complete before and after treatment. Focus on counseling patients about realistic expectations and optimizing your procedural techniques to deliver the best patient outcomes.

VBCA is a CMS-approved Qualified Clinical Data Registry (QCDR) that submits MIPS Measure 420 to the Quality Payment Program (QPP). Practices can report this measure as a MIPS Clinical Quality Measure (CQM) or through qualified registry submission.

🧮MIPS Score Simulator

Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.

Your Performance Rate:%Benchmarks vary by collection type

💡 Tip: Enter your performance rate to compare MIPS points across all collection types. The same rate can score differently depending on how you submit.

2026 MIPS 420 Benchmarks

Historical CMS benchmark deciles for MIPS quality measure 420 by collection type. Your performance rate falls into a decile, which determines your measure points (3–10).

MIPS CQM

Decile	Performance Rate Range	Points

Specialty Measure Sets

Interventional Radiology Vascular Surgery

Related Measures

Patient-Reported Outcomes

MIPS 191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery MIPS 217: Functional Status Change for Patients with Knee Impairments MIPS 218: Functional Status Change for Patients with Hip Impairments MIPS 219: Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments MIPS 220: Functional Status Change for Patients with Low Back Impairments MIPS 221: Functional Status Change for Patients with Shoulder Impairments MIPS 222: Functional Status Change for Patients with Elbow, Wrist or Hand Impairments MIPS 303: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract MIPS 459: Back Pain After Lumbar Surgery MIPS 461: Leg Pain After Lumbar Surgery MIPS 470: Functional Status After Primary Total Knee Replacement MIPS 471: Functional Status After Lumbar Surgery MIPS 478: Functional Status Change for Patients with Neck Impairments MIPS 483: Person-Centered Primary Care Measure Patient Reported Outcome MIPS 485: Psoriasis – Improvement in Patient-Reported Itch Severity MIPS 486: Dermatitis – Improvement in Patient-Reported Itch Severity MIPS 505: Reduction in Suicidal Ideation or Behavior Symptoms

Official Resources

📄 CMS Measure Specification (PDF)🔗 QPP Quality Payment Program

Clinical Context

Clinical Rationale

Surrogate measures to measure the success of varicose vein treatment with saphenous ablation have numerous flaws. The ultimate measure of success of saphenous ablation for varicose veins is an improved quality of life. This quality measure motivates physicians to assess changes in quality of life after as compared with before an ablation using one of several standardized survey instruments.

This enables objective quantification of the improvement in quality of life that saphenous vein ablation provides patients with CEAP C2 disease. Most trials show pain drops fairly quickly but that it plateaus off at about 6 months. There seems to be most improvement by 3 months and some more improvement by 6 months. Therefore, the best time to assess is 3-6 months following treatment (1).

Clinical Recommendations

The Intersocietal Accreditation Commission (IAC) - Vein Center Division strongly recommends the use of the disease specific patient reported outcome (PRO) instruments before and after ablation and to use the data collected for an analysis of the quality of care being delivered by the center. These guidelines have been created by the IAC and are being implemented by several groups including Society for Vascular Surgery (SVS).

The American Venous Forum recommends the use of PRO instruments before and after vein treatment for all patients.

Implementation Notes

This measure contains one strata defined by a single submission criteria. This measure produces a single performance rate. For the purposes of MIPS implementation, this procedure measure is submitted each time a procedure is performed during the performance period.

Frequently Asked Questions

Who is eligible for MIPS 420?

All patients who are treated for varicose veins with saphenous ablation and who receive an outcomes survey within 180 days after treatment.

Is MIPS 420 the same as MIPS 420?

Yes. CMS uses zero-padded three-digit Quality IDs (420) in official specifications, while clinicians often search for MIPS 420 or Quality ID 420 without the leading zero. Both refer to the same 2026 MIPS quality measure reported through the Quality Payment Program (QPP).

What codes do I submit for MIPS 420: Varicose Vein Treatment with Saphenous Ablation: Outcome Survey?

Submission codes: G9603 (Patient survey score improved from baseline following treatment); G9605 (Patient survey score did not improve from baseline following treatment); M1464 (No documentation of at least two attempts to follow up with patient within 180 days of treatment); M1465 (Patient follow up more than 180 days after treatment)

How do I report MIPS Measure 420 in 2026?

MIPS Measure 420 (Quality ID 420) is reported through the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM) via qualified registry, or Medicare Part B claims where applicable.

Is MIPS 420 a topped-out measure?

No, MIPS 420 is not topped out, meaning there is still meaningful performance variation across clinicians.

Report this measure through VBCA

Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.

Learn About Our QCDR →Talk to Us →